Equities research analysts at Piper Jaffray (NYSE: PJC) lowered their price target on shares of AtriCure (NASDAQ: ATRC) to $11.00 in a research issued note to investors on Friday.
Separately, analysts at Morgan Keegan upgraded shares of AtriCure from a “market perform” rating to an “outperform” rating in a research note to investors on Wednesday, August 24th. They now have a $13.00 price target on the stock, down previously from $14.00.
Shares of AtriCure traded down 5.24% during mid-day trading on Monday, hitting $9.41. AtriCure has a 52 week low of $7.38 and a 52 week high of $14.84. The stock’s 50-day moving average is $11. and its 200-day moving average is $12.16. The company has a market cap of $153.0 million.